Hello, Fool! | Login | Signup | My Fool
Jan 9, 2009 10:41 PM ET | Feedback | Site Changes | Help
A biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases.
View All Commentary (ENZN)
Recs
pjani06 (93.66) Submitted: 7/26/08 12:33 PM : Start Price: $7.50 ENZN Score: 5.74
Our demographic picture as well as increased attention to prolonged life will allow this company to easily hit revenues beyond 400 million at the very least within next 5 years. apply a simple 20% oper margin, less potential future debt exp of $40 mil, and you have at least $40 mill left over in net income. multiply that by 10 for a high growth biotech/pharma and this company should be worth atleast $400mill today
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.